AI Article Synopsis

  • The FDA has approved TAVR as a treatment for patients with symptomatic aortic valve stenosis, particularly those at high risk for surgery.
  • Recent guidelines suggest that patients with bio-prosthetic AV stenosis should consider repeat valve replacement, but there's limited support for urgent TAVR in unstable patients.
  • A unique case is presented where emergency TAVR was successfully performed on a hemodynamically unstable patient with severe symptomatic bio-prosthetic AV stenosis.

Article Abstract

FDA approved transcatheter aortic valve replacement (TAVR) for the treatment of symptomatic aortic valve (AV) stenosis. Recent evidence reveals that TAVR is the treatment of choice in most patients with AV stenosis who are at high risk for surgical aortic valve replacement (SAVR). Per AHA guidelines, repeat valve replacement has been recommended for bio-prosthetic AV stenosis. Urgent TAVR for hemodynamically unstable patients with prosthetic AV stenosis is not supported by significant scientific data. However, there have been a few cases reported on emergency TAVR procedures in hemodynamically unstable patients with severe native AV stenosis. We are reporting a unique case of successful emergency TAVR in a hemodynamically unstable patient, who had severe symptomatic bio-prosthetic AV stenosis at the time of presentation.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9617065PMC
http://dx.doi.org/10.34172/jcvtr.2022.04DOI Listing

Publication Analysis

Top Keywords

aortic valve
20
valve replacement
16
hemodynamically unstable
16
successful emergency
8
transcatheter aortic
8
valve stenosis
8
tavr treatment
8
bio-prosthetic stenosis
8
tavr hemodynamically
8
unstable patients
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!